|
gptkbp:instanceOf
|
gptkb:chemical_compound
antiviral drug
antineoplastic agent
DNA methyltransferase inhibitor
|
|
gptkbp:approvedBy
|
gptkb:FDA
|
|
gptkbp:ATCCode
|
L01BC07
|
|
gptkbp:bioavailability
|
24% (subcutaneous)
|
|
gptkbp:brand
|
gptkb:Vidaza
|
|
gptkbp:CASNumber
|
320-67-2
|
|
gptkbp:category
|
gptkb:World_Health_Organization_essential_medicines
orphan drugs
pyrimidine analogues
|
|
gptkbp:chemicalFormula
|
C8H12N4O5
|
|
gptkbp:developedBy
|
University of Czechoslovakia
|
|
gptkbp:discoveredBy
|
1964
|
|
gptkbp:eliminationHalfLife
|
4 hours
|
|
gptkbp:excretion
|
urine
|
|
gptkbp:first_approved_in
|
2004 (US)
|
|
gptkbp:hasSMILES
|
C1=NC(=O)NC(=N1)N2C=NC(=NC2=O)N
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
5-azacytidine
|
|
gptkbp:IUPACName
|
4-amino-1-β-D-ribofuranosyl-1,3,5-triazin-2(1H)-one
|
|
gptkbp:KEGGID
|
D00103
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
inhibits DNA methylation
|
|
gptkbp:MeSH_ID
|
D000073
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:molecularWeight
|
244.21 g/mol
|
|
gptkbp:pregnancyCategory
|
D (US)
|
|
gptkbp:PubChem_CID
|
9444
CHEMBL1387
9071
|
|
gptkbp:relatedTo
|
gptkb:decitabine
|
|
gptkbp:routeOfAdministration
|
subcutaneous
intravenous
|
|
gptkbp:sideEffect
|
gptkb:anemia
fever
nausea
vomiting
neutropenia
thrombocytopenia
injection site reactions
|
|
gptkbp:synonym
|
gptkb:azacitidine
|
|
gptkbp:UNII
|
K9A2V3S8F4
|
|
gptkbp:usedFor
|
gptkb:acute_myeloid_leukemia
myelodysplastic syndromes
|
|
gptkbp:bfsParent
|
gptkb:DNA_methyltransferase
|
|
gptkbp:bfsLayer
|
7
|